| Reassessing Pharmacokinetics in Plant Extracts: A Case Study of Oleandrin and Its Hydroalcoholic Extract   |   |
|--|---|
| Sara Abdennour <sup>1</sup> , Mohamed Tahar Taha Derouiche <sup>1</sup> , Ludovic Romeuf <sup>2</sup> , Yvan Gaillard <sup>2</sup> , Farid Dalia <sup>1</sup> , Mohamed Azzouz Ah BOUBNIDEF<br>1. Pharmacy Department, Medicine Faculty, University of Constantine 3, Algeria  |   |
| <ol> <li>Lat lumtox Laboratory, France</li> <li>Toxicology Laboratory, Pharmacy Faculty, Algiers 1 University, Algeria</li> <li>sara.abdennour@univ-constantine3.dz</li> </ol>   |   |
| INTRODUCTION AND OBJECTIVE   |   |
| Preclinical toxicology, essential for drug registration, provides some measure of potential human<br>risk. Due to complex composition, it's crucial to assess plant extract pharmacokinetics when<br>therapeutically relevant, as active compound pharmacokinetics may differ.<br>Oleandrin, the active and toxic compound of <i>Nerium oleander L</i> has garnered significant interest in<br>recent years due to its anti-tumor and anti-viral properties.<br><b>Aim</b><br>The objective of this work is to illustrate the necessity of reassessing pharmacokinetics depending<br>on the plant extracts, using the pharmacokinetics of oleandrin in the alcoholic extract of Nerium<br>oleander, compared to published data on its pharmacokinetics when administered in its pure form. |   |
| METHODS  |   |
| EXPERIEMENT  | LITERATURE <sup>(3)</sup>   |
| MIXTURE  | ISOLATED COMPOUND   |
| • A hydroalcoholic extract was used : <i>Nerium oleander</i> leaves<br>underwent a process involving powdering, maceration in 70%<br>ethanol, filtration, rotary evaporation and lyophilization.   | • <sup>3</sup> H oleandrin was used.  |
| <ul> <li>Pharmacokinetic studies of oleandrin were conducted in Swiss<br/>male mice after administering both intravenous (I.V.) and oral<br/>(P.O.) doses of a hydroalcoholic extract of Nerium oleander.</li> </ul>   | <ul> <li>Pharmacokinetic studies were conducted in male CD1-mice<br/>after administering both intravenous (I.V.) and oral (P.O.)<br/>doses of <sup>3</sup>H oleandrin.</li> </ul> |
| <ul> <li>For oral studies, a dose of 150 mg/g was administered (equivalent dose of 1710 µg/kg) via gastric feeding, with seven sampling times at 10, 20, 30, 40, 60, 120 and 180 min.</li> <li>Intravenous studies involved a dose of 30 mg/g (equivalent dose of 342 µg/kg) administered through injection, with</li> </ul>   | <ul> <li>Intravenous (IV) administration involved a dose of 40 μg/kg,<br/>while oral studies utilized a dose of 80 μg/kg.</li> </ul>  |
| <ul> <li>sampling times at 10, 30, 60, and 120 minutes.</li> <li>Excretion studies utilized seven mice, administered a dose of 150 mg/g, with urine samples collected at 48 hours.</li> </ul>  | <ul> <li>Excretion used a dose of 40 µg/kg, with urine samples<br/>collected at 0, 4, 7, 24 and 48 hours.</li> </ul>  |
| <ul> <li>Sample preparation involved mixing samples with a deuterated<br/>standard solution and acetonitrile, followed by LC-MS/MS<br/>analysis.</li> </ul>  | <ul> <li>LC-MS/MS was employed for oleandrin quantification.</li> </ul>   |
| <ul> <li>Pharmacokinetic parameters were calculated using PK Solver<br/>2.0 software.</li> </ul>   | <ul> <li>Pharmacokinetic parameters were calculated using WinNonlin 3.1.</li> </ul>   |
| RESULTS AND DISCUSSION   |   |
| Cmax at 10 min.  | Cmax at 20 min.   |
| Bioavailability of 61.6 %.   | Bioavailability of 29.3 %.  |
| • The apparent volume of distribution Vss was 0.55 L/kg.   | • The apparent volume of distribution Vss was 0.3±0.2 L/kg.   |
| <ul> <li>Clearance CIT was 0.01 kg* L/min.</li> </ul>  | <ul> <li>Clearance CIT was 1.13±0.41 L/h.kg.</li> </ul>   |
| <ul> <li>Oleandrin in urine represents 0.986% of the initial dose administred.</li> </ul>  | • Oleandrin in urine represents 1.9 % of the injected dose.   |
| Oleandrin in the extract has been absorbed faster (Tmax 10 min vs. 20 min alone).<br>Extract bioavailability (61%) is double that of oleandrin alone (30%), likely due to absorption-enhancing substances, possibly P-<br>glycoprotein inhibitors.   |   |
| CONCLUSION   |   |
| In conclusion, this study highlights the importance of reevaluating pharmacokinetics when working with plant extracts. Specifically, distinct pharmacokinetic profiles for oleandrin in its pure form versus an hydroalcoholic extract of <i>Nerium oleander</i> were observed. These findings underscore the complexity of plant extract pharmacokinetics, emphasizing the need for thorough assessments in herbal research.  |   |
| BIBLIOGRAPHY   |   |
| <ol> <li>Sharma R, Singh S, Tewari N, Dey P. A toxic shrub turned therapeutic: The dichotomy of Nerrium oleander bioactivities. Toxicon. 2023;224:107047.</li> <li>Mamindla S, K.V.S.R.G P, Koganti B. Herb-Drug Interactions: An Overview Of Mechanisms And Clinical Aspects. IJPSR. 2016;7(9).</li> <li>Ni D, Madden TL, Johansen M, Felix E, Ho DH, Newman RA. Murine pharmacokinetics and metabolism of oleandrin, a cytotoxic component of Nerium oleander. J Exp Ther Oncol. 2002;2(5):278-285.</li> </ol>   |   |